NYSE: GMREGlobal Medical Reit Inc Stock
$7.60-0.02 (-0.26%)
Updated Sep 17, 2025
GMRE Price
$7.60
Fair Value Price
N/A
Market Cap
$508.28M
52 Week Low
$6.06
52 Week High
$10.46
P/E
108.57x
P/B
1.01x
P/S
3.26x
PEG
0.48x
Dividend Yield
10.26%
Revenue
$142.01M
Earnings
$10.29M
Gross Margin
100%
Operating Margin
28.36%
Profit Margin
3.1%
Debt to Equity
1.53
Operating Cash Flow
$71M
Beta
0.84
Next Earnings
Nov 5, 2025
Ex-Dividend
Sep 29, 2025
Next Dividend
Oct 15, 2025
GMRE Overview
Global Medical REIT Inc. leases purpose-built healthcare facilities in select markets to clinical operators with dominant market share. Its facilities include surgery centers, specialty hospitals, and outpatient treatment centers. Global Medical REIT was founded in 2011 and is headquartered in Bethesda, MD.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GMRE's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Healthcare Facility REIT
Industry Rating
D
GMRE
Ranked#13 of 16
Ranked#13 of 16
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.26 | B | |
| $34.28 | C | |
| $15.23 | C |
Be the first to know about important GMRE news, forecast changes, insider trades & much more!
GMRE News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GMRE scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GMRE ($7.60) is trading above its intrinsic value of $6.46, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GMRE is poor value based on its earnings relative to its share price (108.57x), compared to the US market average (37.36x)
P/E vs Market Valuation
GMRE is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more GMRE due diligence checks available for Premium users.
Valuation
GMRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
108.57x
Industry
76.21x
Market
37.36x
GMRE is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
GMRE is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
GMRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.01x
Industry
2.42x
GMRE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GMRE price to earnings growth (PEG)
For valuing profitable companies with growth potential
GMRE is good value based... subscribe to Premium to read more.
PEG Value Valuation
GMRE's financial health
Profit margin
Revenue
$38.0M
Net Income
$655.0k
Profit Margin
-2.1%
GMRE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.3B
Liabilities
$771.9M
Debt to equity
1.53
GMRE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GMRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$22.1M
Investing
-$39.2M
Financing
$18.7M
GMRE vs Healthcare Facility REIT Stocks
Global Medical Reit Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.